IDENTIFICATION OF TYROSINE-154 AND TYROSINE-307 IN THE EXTRACELLULAR DOMAIN AND TYROSINE-653 AND TYROSINE-766 IN THE INTRACELLULAR DOMAIN AS PHOSPHORYLATION SITES IN THE HEPARIN-BINDING FIBROBLAST GROWTH-FACTOR RECEPTOR TYROSINE KINASE (FLG)

被引:0
|
作者
HOU, JZ
MCKEEHAN, K
KAN, MK
CARR, SA
HUDDLESTON, MJ
CRABB, JW
MCKEEHAN, WL
机构
[1] W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946
[2] SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406
关键词
GROWTH FACTORS; ONCOGENES; SIGNAL TRANSDUCTION;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Four tyrosine residues have been identified as phosphorylation sites in the tyrosine kinase isoform of the heparin-binding fibroblast growth factor receptor flg (FGF-R1). Baculoviral-insect cell-derived recombinant FGF-R1 was phosphorylated and fragmented with trypsin while immobilized on heparin-agarose beads. Phosphotyrosine peptides were purified by chromatography on immobilized anti-phosphotyrosine antibody and analyzed by Edman degradation and electrospray tandem mass spectrometry. Tyrosine residue 653, which is in a homologous spatial position to major autophosphorylation sites in the catalytic domain of the src and insulin receptor kinases, is the major intracellular FGF-R1 phosphorylation site. Residue 766 in the COOH-terminus outside the kinase domain is a secondary site. Tyrosine residues 154 and 307, which are in the extracellular domain of transmembrane receptor isoforms and are in an unusual sequence context for tyrosine phosphorylation, were also phos phorylated.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 47 条
  • [41] MECHANISMS OF 4-HYDROXYTAMOXIFEN ANTI-GROWTH FACTOR ACTIVITY IN BREAST-CANCER CELLS - ALTERATIONS OF GROWTH-FACTOR RECEPTOR-BINDING SITES AND TYROSINE KINASE-ACTIVITY
    FREISS, G
    ROCHEFORT, H
    VIGNON, F
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (03) : 919 - 926
  • [42] Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation - A critical role for Cbl tyrosine kinase-binding domain
    Miyake, S
    Mullane-Robinson, KP
    Lill, NL
    Douillard, P
    Band, H
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (23) : 16619 - 16628
  • [43] Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor
    Sugita, S
    Kawashima, H
    Tanaka, T
    Kurisu, T
    Sugimura, K
    Nakatani, T
    ONCOLOGY REPORTS, 2004, 11 (06) : 1273 - 1279
  • [44] Vascular Endothelial Growth Factor Receptor, fms-Like Tyrosine Kinase-1 (Flt-1), as a Novel Binding Partner for SARS-CoV-2 Spike Receptor-Binding Domain
    Mutahar, Adel Zaid I.
    Devaramani, Manjunath
    Dayal, Renu
    Saini, Dinesh Kumar
    Salimath, Paramahans V.
    Salimath, Bharathi P.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] TYROSINE MUTATIONS WITHIN THE ALPHA-PLATELET-DERIVED GROWTH-FACTOR RECEPTOR KINASE INSERT DOMAIN ABROGATE RECEPTOR-ASSOCIATED PHOSPHATIDYLINOSITOL-3 KINASE-ACTIVITY WITHOUT AFFECTING MITOGENIC OR CHEMOTACTIC SIGNAL TRANSDUCTION
    YU, JC
    HEIDARAN, MA
    PIERCE, JH
    GUTKIND, JS
    LOMBARDI, D
    RUGGIERO, M
    AARONSON, SA
    MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (07) : 3780 - 3785
  • [46] Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking
    Lanotte, Romain
    Garambois, Veronique
    Gaborit, Nadege
    Larbouret, Christel
    Musnier, Astrid
    Martineau, Pierre
    Pelegrin, Andre
    Chardes, Thierry
    CANCER SCIENCE, 2020, 111 (07) : 2508 - 2525
  • [47] Inhibition of Ehrlich ascites cancer, hypoxia-inducible factor-1 alpha, and the kinase insert domain-containing receptor/fms-like tyrosine kinase-binding domains of vascular endothelial growth factor by Thiazole Acetamide Derivatives
    Madhu, L. N.
    Telkar, Sandeep
    Kamath, Divyalaxmi
    Souza, Melita Evan D.
    Rao, Shama
    Nayak, Prakash S.
    Sarojini, B. K.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 : S74 - S81